The Novel Variant NP_00454563.2 ( p.Glu259Glyfs77 ) in Gene PKP2 Associated with Arrhythmogenic Cardiomyopathy in 8 Families from Malaga, Spain

• Published in: Genes Vol. 14; no. 7; p. 1468
• Main Authors: Robles-Mezcua, Ainhoa, Ruíz-Salas, Amalio, Medina-Palomo, Carmen, Robles-Mezcua, María, Díaz-Expósito, Arancha, Ortega-Jiménez, María Victoria, Gimeno-Blanes, Juan Ramón, Jiménez-Navarro, Manuel F, García-Pinilla, José Manuel
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19-07-2023; MDPI
• Subjects: Cardiac arrhythmia; Cardiomyopathy; Cardiovascular disease; Congestive heart failure; Diagnosis; Family medical history; Founder effect; Genes; Genetic diversity; Genetic screening; Genetic testing; Genomics; Genotype & phenotype; Heart diseases; Heart failure; Myocardium; Next-generation sequencing; Pathogenesis; Patients; Variables; Ventricle; Spain; PKP2; heart failure; arrhythmic events; genetic variant; arrhythmogenic cardiomyopathy
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes14071468

Arrhythmogenic cardiomyopathy (ACM) is a hereditary heart disease defined by the progressive replacement of the ventricular myocardium with fibroadipose tissue, which can act as a substrate for arrhythmias, sudden death, or even give rise to heart failure (HF). Sudden death is frequently the first manifestation of the disease, particularly among young patients. The aim of this study is to describe a new pathogenic variant in the
.
A descriptive observational study that included eight initially non-interrelated families with a diagnosis of ACM undergoing follow-up at our HF and Familial Cardiomyopathies Unit, who were carriers of the NM_004572.3:c.775_776insG;
variant in the
. The genetic testing employed next-generation sequencing for the index cases and the Sanger method for the targeted study with family members. We compiled personal and family histories, demographic and clinical characteristics, data from the additional tests at the time of diagnosis, and arrhythmic events at diagnosis and during follow-up.
We included 47 subjects, of whom 8 were index cases (17%). Among the evaluated family members, 16 (34%) were carriers of the genetic variant, 3 of whom also had a diagnosis of ACM. The majority were women (26 patients; 55.3%), with a mean age on diagnosis of 48.9 ± 18.6 years and a median follow-up of 39 [24-59] months. Worthy of note are the high incidences of arrhythmic events as the form of presentation and in follow-up (21.5% and 20.9%, respectively), and the onset of HF in 25% of the sample. The most frequent ventricular involvements were right (four patients, 16.7%) and biventricular (four patients, 16.7%); we found no statistical differences in any of the variables analysed.
This variant is a pathogenic variant of gene
that has not previously been described and is not present in the control groups associated with ACM. It has incomplete penetrance, a highly variable phenotypic expressivity, and was identified in eight families of our geographical area in Malaga (Andalusia, Spain), suggesting a founder effect in this area and describe the clinical and risk characteristics.